Michigan Medicine is the coordinating center for the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE). Formed in early 2020, the consortium consists of 18 academic institutions working together to create a powerful clinical-genomic platform to interrogate and address data gaps that have arisen with increased genomic testing in the clinical management of prostate cancer.
Over the last decade, advancements in genomic sequencing technologies have allowed for a deeper understanding of the molecular complexity of metastatic castrate-resistant prostate cancer (mCRPC). Many potentially actionable alterations are now identified, fueling biomarker-based clinical trials of novel molecularly targeted agents as well as standard therapies.
With this shifting paradigm and advancements in technology, there will be a rise in availability, breadth, and scope of genomic data derived from CLIA-based testing platforms. Linkage of this data with granular patient outcomes can be leveraged to improve our understanding of the molecular mechanisms that lead to variable clinical outcomes across prostate cancer disease states over time, identify additional subgroups of patients whose tumors are more vulnerable to specific therapies and help guide decisions of optimal sequencing of therapies in prostate cancer.
To better inform future clinical care and precision medicine approaches by:
- establishing a large, diverse, inclusive, and well-annotated repository of completely de-identified clinical and genomic patient data that is linked to clinical characteristics and disease-related outcomes.
- investigating prognostic and potentially predictive biomarkers in patients with advanced prostate cancer treated with approved therapies including genomic, transcriptomic, and proteomic biomarkers.
Ajjai Alva, MD
Clinical Professor
Division of Hematology & Oncology
Rogel Cancer Center
1500 E. Medical Center Drive
Ann Arbor, Michigan 48109-5912
The PROMISE Consortium is made up of 18 academic institutions, all with the common goal of understanding real-world data in patients with advanced prostate cancer in order to improve outcomes. We hope to expand the reach of the database to include many more academic institutions and community practices to further diversify the patient population and more representative of the real-world setting.
- Case Comprehensive Cancer Center (Cleveland, OH)
- City of Hope (Duarte, CA)
- Duke Cancer Institute (Durham, NC)
- Emory University (Atlanta, GA)
- Henry Ford Health System (Detroit, MI)
- Johns Hopkins University School of Medicine (Baltimore, MD)
- Karmanos Cancer Institute (Detroit, MI)
- Medical College of Wisconsin (Milwaukee, WI)
- Michigan Medicine (Ann Arbor, MI)
- Oregon Health & Science University Knight Cancer Institute (Portland, OR)
- Tulane University (New Orleans, LA)
- University of California San Diego (San Diego, CA)
- University of California San Francisco (San Francisco, CA)
- University of Colorado Denver (Denver, CO)
- University of Iowa (Iowa City, IA)
- University of Oklahoma (Oklahoma City, OK)
- University of Washington (Seattle, WA)
- Weill Cornell Medical Center (New York, NY)
The PROMISE consortium was formed with the recognition of the significant clinical and research needs of linking clinical and genomic data to outcomes in order to better inform treatment decisions and outcomes for patients with advanced prostate cancer. Data collected in this consortium will address significant knowledge gaps that come about as the underlying biology of prostate cancer becomes better understood and multiple novel agents and classes of drugs emerge as treatment options.
- Administrative Headquarters - maintains RedCap database and manages the development of the consortium
- Bio-Informatics Committee - standardizes genomic data and provides quality control
- Biostatistics Committee - independently performs statistical analyses
- Diversity/Inclusion Committee - addresses important clinical questions pertaining to racial disparities
- Executive Committee - reviews and selects proposals of relevant questions for the consortium to address
- Patient Advocacy Committee - provides patient perspectives to improve patients’ quality of care
- Data collection
- Quality control
- Project development
- Data analysis
- Release date (abstract/manuscript)
